240 17 JANUARY 2020 • VOL 367 ISSUE 6475 sciencemag.org SCIENCE
ILLUSTRATION: DAVIDE BONAZZI/SALZMAN ART
FEATURES
F
or 20 years, the U.S. government
has urged companies, universities,
and other institutions that conduct
clinical trials to record their results
in a federal database, so doctors
and patients can see whether new
treatments are safe and effective.
Few trial sponsors have consis-
tently done so, even after a 2007
law made posting mandatory for many tri-
als registered in the database. In 2017, the
National Institutes of Health (NIH) and
the Food and Drug Administration (FDA)
tried again, enacting a long-awaited “final
rule” to clarify the law’s expectations and
penalties for failing to disclose trial results.
The rule took full effect 2 years ago, on
18 January 2018, giving trial sponsors am-
ple time to comply. But a Science investi-
gation shows that many still ignore the
requirement, while federal officials do little
or nothing to enforce the law.
Science examined more than 4700 tri-
als whose results should have been posted
on the NIH website ClinicalTrials.gov
under the 2017 rule. Reporting rates by
most large pharmaceutical companies and
some universities have improved sharply,
but performance by many other trial
sponsors—including, ironically, NIH itself—
was lackluster. Those sponsors, typically
either the institution conducting a trial or
its funder, must deposit results and other
data within 1 year of completing a trial. But
of 184 sponsor organizations with at least
five trials due as of 25 September 2019,
30 companies, universities, or medical cen-
ters never met a single deadline (see https://
scim.ag/ctgov). As of that date, these habit-
ual violators had failed to report any results
for 67% of their trials and averaged 268 days
late for those and all trials that missed their
deadlines. They included such eminent
Many clinical trial results aren’t posted publicly, as U.S. law requires—
and a promised crackdown has fizzled
By Charles Piller
TRANSPARENCY ON TRIAL
Published by AAAS